Qyuns Therapeutics Co., Ltd.

Partners

Qyuns has established in-depth strategic cooperations with a number of leading pharmaceutical enterprises around the world. We strive to integrate superior resources, empower each other and accelerate drug innovation in order to maximize the global value of our pipelines and thus to benefit patients with safer, more effective and more affordable treatments as soon as possible.

Why cooperate with us?

We are a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline and an established commercial-scale in-house manufacturing capability.Strengthening cooperation and striving for win-win results has always been one of our core strategies.

Research & Devlopment

Exclusive focus on autoimmune and allergic diseases, with comprehensive coverage of four major disease areas and deep knowledge of key therapeutic pathways
Pipeline

One of China’s most comprehensive and advanced pipelines of biologics in autoimmune and allergic diseases
Rabbit Antibody

Development Platform: The rabbit antibody development platform is the foundation for our drug discovery and development, covering all core antibody development functions.
Integrated Industrial Capability

We have the capability from discovery to commercialization
Management Team

A visionary management team with rich industry experience and successful entrepreneurial track records

Collaboration

01Cooperative Development

Qyuns is developing a series of antibody drugs targeting autoimmune and allergic diseases. We are willing to collaborate with potential partners who plans to set foot in the field of autoimmune and allergic diseases and have corresponding resources or advantages to develop intended drugs or expand their indication layout, and jointly promote commercialization.
02Authorization License

In order to further leverage the value of pipelines and maximize the commercial potential of our products, we plan to authorize the pipeline products in the pipelines as a whole, or by region or indication, to our partners. We believe that relevant strategic cooperation can improve the accessibility of our drugs in the fastest and most cost-effective way.
03Sales Collaboration

We are also considering sales collaboration with partners who have strong sales channels for autoimmune or allergic diseases, to jointly promote commercialization in relevant fields and exploit market opportunities as widely as possible.